<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>335</serviceExecutionTime><Drug id="32431"><DrugName>ReN-1820</DrugName><DrugSynonyms><Name><Value>ReN-1820</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>hNGF, ReNeuron</Value></Name><Name><Value>hNGF, Enact/University of Bristol</Value></Name><Name><Value>human nerve growth factor, ReNeuron</Value></Name><Name><Value>human nerve growth factor, Enact/University of Bristol</Value></Name><Name><Value>TrkAd5</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="20544">University of Bristol</CompanyOriginator><CompaniesSecondary><Company id="20544">University of Bristol</Company><Company id="27799">ReNeuron Group plc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="32431" type="Drug"><TargetEntity id="420307" type="siDrug">TrkAd-5</TargetEntity></SourceEntity><SourceEntity id="20544" type="Company"><TargetEntity id="4296787325" type="organizationId">University of Bristol</TargetEntity></SourceEntity><SourceEntity id="27799" type="Company"><TargetEntity id="4295894218" type="organizationId">ReNeuron Group PLC</TargetEntity></SourceEntity><SourceEntity id="188" type="ciIndication"><TargetEntity id="10061218" type="MEDDRA"></TargetEntity><TargetEntity id="D007249" type="MeSH"></TargetEntity><TargetEntity id="-308860612" type="omicsDisease"></TargetEntity><TargetEntity id="1181" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="20" type="ciIndication"><TargetEntity id="10033371" type="MEDDRA"></TargetEntity><TargetEntity id="D010146" type="MeSH"></TargetEntity><TargetEntity id="-1585850437" type="omicsDisease"></TargetEntity><TargetEntity id="1" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="233" type="ciIndication"><TargetEntity id="10053643" type="MEDDRA"></TargetEntity><TargetEntity id="D019636" type="MeSH"></TargetEntity><TargetEntity id="-1502359765" type="omicsDisease"></TargetEntity><TargetEntity id="160" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="403" type="ciIndication"><TargetEntity id="N30" type="ICD10"></TargetEntity><TargetEntity id="10011781" type="MEDDRA"></TargetEntity><TargetEntity id="D003556" type="MeSH"></TargetEntity><TargetEntity id="-1776447469" type="omicsDisease"></TargetEntity><TargetEntity id="941" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="264" type="Action"><TargetEntity id="1956" type="Mechanism">Low-affinity Nerve Growth Factor Receptor LNGFRp75 Antagonists</TargetEntity><TargetEntity id="5466" type="Mechanism">Nerve Growth Factor (NGF) Antagonists</TargetEntity><TargetEntity id="2611" type="Mechanism">Anti-Nerve Growth Factor (NGF)</TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-01422" type="ciTarget"><TargetEntity id="9364897148043" type="siTarget">Tumor necrosis factor receptor superfamily member 16</TargetEntity><TargetEntity id="526" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="188">Inflammatory disease</Indication><Indication id="20">Pain</Indication><Indication id="233">Neurodegenerative disease</Indication><Indication id="403">Cystitis</Indication></IndicationsSecondary><ActionsPrimary><Action id="264">NGF receptor antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="284">Nootropic agent</Action><Action id="2946">Analgesic</Action><Action id="2953">Anti-inflammatory</Action><Action id="5557">Muscle relaxant</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>N6D</Code><Name>NOOTROPICS</Name></Ephmra><Ephmra><Code>M3</Code><Name>MUSCLE RELAXANTS</Name></Ephmra><Ephmra><Code>N2</Code><Name>ANALGESICS</Name></Ephmra></EphmraCodes><LastModificationDate>2018-01-12T22:40:41.000Z</LastModificationDate><ChangeDateLast>2016-10-27T00:00:00.000Z</ChangeDateLast><AddedDate>2001-01-17T12:56:25.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="27799" linkType="Company"&gt;ReNeuron&lt;/ulink&gt;,  under license from  the &lt;ulink linkID="20544" linkType="Company"&gt;University of Bristol&lt;/ulink&gt; (from work funded by &lt;ulink linkID="28448" linkType="Company"&gt;Enact&lt;/ulink&gt;), was investigating ReN-1820 (TrkAd5), a soluble recombinant human nerve growth factor (hNGF) antagonist,  for the potential treatment of pain, inflammation , neurodegenerative diseases including Alzheimer's disease (AD) and cystitis [&lt;ulink linkID="396184" linkType="reference"&gt;396184&lt;/ulink&gt;], [&lt;ulink linkID="456055" linkType="reference"&gt;456055&lt;/ulink&gt;], [&lt;ulink linkID="793335" linkType="Reference"&gt;793335&lt;/ulink&gt;].  In October 2004, the company took the strategic decision to focus on the commercial exploitation of stem cell technologies and was seeking to outlicense soluble receptor programs. At that time,  Ren-1820 was no longer listed on the company pipeline [&lt;ulink linkID="562802" linkType="Reference"&gt;562802&lt;/ulink&gt;].    &lt;/para&gt;&lt;/Summary&gt;</value></Summary><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In November 2005, preclinical data were published which described the design, expression, refolding and purification of ReN-1820. The compound was shown to bind nerve growth factor with picomolar affinity and was stable in both blood and urine. Furthermore, ReN-1820  was demonstrated to be effective in animal models of inflammatory pain and allergic asthma [&lt;ulink linkID="792969" linkType="Reference"&gt;792969&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In August 2003, ReNeuron reported data that were to be presented at the Research Insights into Interstitial Cystitis Symposium,  in Alexandria, VA, later that year. In the study, ReN-1820 delayed the  onset and  markedly reduced the frequency and strength of bladder contractions in a model of cystitis [&lt;ulink linkID="79335" linkType="Reference"&gt;&lt;/ulink&gt;&lt;ulink linkID="793335" linkType="Reference"&gt;793335&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;In November 2001, ReNeuron was intending to test the compound in several in vivo models to choose the lead target indications [&lt;ulink linkID="516178" linkType="reference"&gt;516178&lt;/ulink&gt;]. This work was ongoing in June 2002, and manufacture of the protein was being scaled up in preparation for clinical trials [&lt;ulink linkID="456055" linkType="reference"&gt;456055&lt;/ulink&gt;], [&lt;ulink linkID="464522" linkType="reference"&gt;464522&lt;/ulink&gt;]. By June 2002, ReN-1820 had been shown in vivo to be able to reduce the painful effects of NGF injection, indicating that the soluble receptor fragment was able to act as a binding decoy for NGF [&lt;ulink linkID="456055" linkType="reference"&gt;456055&lt;/ulink&gt;]. In January 2003, significant progress of the scale-up production of ReN-1820 was reported [&lt;ulink linkID="478016" linkType="reference"&gt;478016&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;By the end of November 2000,  the study of ReN-1820 for the treatment of AD; the study of nerve regeneration using neurotropins, which the company had demonstrated results in directed, rather than random, growth; the study of hNGF biomimetics; and applications of IgV2 for the treatment of pain in cancer had been conducted [&lt;ulink linkID="396184" linkType="reference"&gt;396184&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In November 2001, ReNeuron licensed this program from Enact Pharma, who had shared a research collaboration with the University of Bristol. By that time,  the University of Bristol had identified and patented the specific binding regions of neurotrophin receptors, which had been cloned and expressed as soluble receptors that show full biological activity [&lt;ulink linkID="516178" linkType="reference"&gt;516178&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 1999,  &lt;ulink linkID="IN2736654" linkType="Patent"&gt;WO-9953055&lt;/ulink&gt; was published, which claimed  the use of a domain of Trk as a therapeutic agent and for screening purposes and rational design of NGF mimetics.&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="27799">ReNeuron Group plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="20">Pain</Indication><StatusDate>2004-10-06T00:00:00.000Z</StatusDate><Source id="562802" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="27799">ReNeuron Group plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="188">Inflammatory disease</Indication><StatusDate>2004-10-06T00:00:00.000Z</StatusDate><Source id="562802" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="27799">ReNeuron Group plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="233">Neurodegenerative disease</Indication><StatusDate>2004-10-06T00:00:00.000Z</StatusDate><Source id="562802" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="27799">ReNeuron Group plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="403">Cystitis</Indication><StatusDate>2004-10-06T00:00:00.000Z</StatusDate><Source id="562802" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20544">University of Bristol</Company><Country id="GB">UK</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate>2001-11-29T00:00:00.000Z</StatusDate><Source id="516178" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20544">University of Bristol</Company><Country id="GB">UK</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="233">Neurodegenerative disease</Indication><StatusDate>2001-11-29T00:00:00.000Z</StatusDate><Source id="516178" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="20544">University of Bristol</Company><Country id="GB">UK</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate>2001-01-17T00:00:00.000Z</StatusDate><Source id="396184" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20544">University of Bristol</Company><Country id="GB">UK</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="233">Neurodegenerative disease</Indication><StatusDate>2001-01-17T00:00:00.000Z</StatusDate><Source id="396184" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="27799">ReNeuron Group plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="188">Inflammatory disease</Indication><StatusDate>2002-06-25T00:00:00.000Z</StatusDate><Source id="456055" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="27799">ReNeuron Group plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate>2001-11-29T00:00:00.000Z</StatusDate><Source id="516178" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="27799">ReNeuron Group plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="403">Cystitis</Indication><StatusDate>2003-08-22T00:00:00.000Z</StatusDate><Source id="793335" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="27799">ReNeuron Group plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="233">Neurodegenerative disease</Indication><StatusDate>2001-11-29T00:00:00.000Z</StatusDate><Source id="516178" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-01422"><Name>NGF receptor</Name><SwissprotNumbers><Swissprot>P07174</Swissprot><Swissprot>P08138</Swissprot><Swissprot>P18519</Swissprot><Swissprot>Q9Z0W1</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="20544">University of Bristol</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="27799">ReNeuron Group plc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="122566" title="ReNeuron to develop the University of Bristol's neurotrophin receptor therapeutics"/></Deals><hasSWOTs>N</hasSWOTs></Drug></drugRecordsOutput>